MedTrace Logo

Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

NCT00676260 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2012-02-28

No results posted yet for this study

Summary

The purpose of this study is to measure microcirculation in type 2 diabetes patients with peripheral edema who are taking pioglitazone, once daily (QD).

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks

DRUG

Placebo

Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2004-08-31
Completion
2004-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676260 on ClinicalTrials.gov